<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The translocation t(14;18)(q32;q21), characteristic for follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and a subset of diffuse large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, juxtaposes the bcl-2 proto-oncogene with the Ig heavy-chain (IgH) gene </plain></SENT>
<SENT sid="1" pm="."><plain>This results in deregulation of the bcl-2 gene expression and elevation of BCL-2 protein, which protects the cells against induction of programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> and, thus, confers a survival advantage leading to immortalization of t(14;18)-carrying cells </plain></SENT>
<SENT sid="2" pm="."><plain>The acquisition of additional chromosomal aberrations is necessary for the <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> and clonal progression of BCL-2 overexpressing lymphocytes </plain></SENT>
<SENT sid="3" pm="."><plain>These secondary changes can be observed by karyotyping in more than 90% of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with t(14;18).1,2 </plain></SENT>
</text></document>